As reported in national media, healthcare companies such as Baxter are experiencing unprecedented demand, up to three times the normal orders, for our dialysis equipment which is used in the Intensive Care Unit. These demands are not just in the UK but across the globe as medical teams treat patients with COVID-19.
We know and understand how challenging this situation is for healthcare providers across the UK and we have mobilised our entire organisation to respond.
This dialysis called Continuous Renal Replacement Therapy (CRRT) is an effective option for patients with acute kidney injury. CRRT filters the blood over 24 hours, mimicking the action of the kidney and keeping fluid levels in the body relatively constant. There are several options for CRRT. The type used depends on the patient's specific condition.
Over the past few weeks Baxter has been undertaking many measures to ensure we can continue to provide as much product as we are able to across the globe and specifically in the UK. The main products included are the devices, fluids and then sets, or tubing which has special filters attached.
We have been working in close partnership with the Department of Health and Social Care and NHS England to make sure supplies are allocated to hospitals across UK where the need is greatest.
Where possible and appropriate we are applying EU and UK regulatory flexibilities developed to support the healthcare products supply chain in response to the COVID-19 outbreak. These can minimise the time between our products being made, to them being available to send to customers. This means we will be able to get product from our manufacturing facilities to our distribution centre and then out to customers more quickly. With the agreement of the regulatory authorities we are also sourcing alternative stocks of critical products.
All our manufacturing facilities have added additional shifts where possible so that they are all running 24 hours a day, 7 days a week.
As a global company we are seeing this demand across the world and we are using our pandemic allocation protocol to fairly distribute product to hot spot areas where the need is greatest
This does not impact our supplies of peritoneal dialysis or haemodialysis which are used for the treatment of chronic renal failure.